Anidulafungin

Phase 1/2Completed
0 watching 0 views this week Active
40
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neutropenia

Conditions

Neutropenia

Trial Timeline

Jul 1, 2003 → Jun 1, 2004

About Anidulafungin

Anidulafungin is a phase 1/2 stage product being developed by Pfizer for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00056381. Target conditions include Neutropenia.

Hype Score Breakdown

Clinical
13
Activity
8
Company
9
Novelty
4
Community
3

Clinical Trials (5)

NCT IDPhaseStatus
NCT01202253Pre-clinicalCompleted
NCT00934934Phase 2Terminated
NCT01053884Phase 2Terminated
NCT00537329Phase 3Completed
NCT00056381Phase 1/2Completed